Genetic immunization with the immunodominant antigen P48 of Mycoplasma agalactiae stimulates a mixed adaptive immune response in BALBc mice

A DNA vaccine against contagious agalactia was developed for the first time, encoding the P48 of Mycoplasma agalactiae. Specific immune responses elicited in BALB/c mice were evaluated. Both total IgG and IgG1 were detected in mice vaccinated with pVAX1/P48. Proliferation of mononuclear cells of the spleen, levels of gamma interferon, interleukin-12, and interleukin-2 mRNAs were enhanced in immunized animals. Results indicate that pVAX1/P48 vaccination induced both T(h)1 and T(h)2 immune responses. Nucleic acid immunization could be a new strategy against M. agalactiae infections and may be potentially used to develop vaccines for other Mycoplasma diseases

Efficacy of a diet containing caseinate hydrolysate on signs of stress in dogs

The purpose of this randomized, double blind, placebo-controlled trial was to evaluate 3 the efficacy of a diet containing caseinate hydrolysate (CH) on signs of stress in 2 4 groups of dogs (defined as Anxious and Non-anxious) using physiological (serum 5 cortisol and lysozyme, N:L ratios and heart rate) and behavioral parameters. 6 From an initial group of 40 female Beagle dogs, ranging in age from 10 months to 4 7 years (mean = 1.47 years; SD = 0.53) belonging to a dog colony, 32 were selected for 8 this study according to their level of anxiety. A group of 16 Anxious dogs and a group 9 of 16 Non-anxious dogs were identified. 10 A baseline period, aimed to obtain reference values of investigated parameters, 11 preceded the experimental phase. Both groups (Anxious and Non-anxious) were divided 12 into a treatment group, which received the diet containing CH, and a control group 13 which received a placebo diet (PD). Anxious CH and PD groups were balanced for 14 anxiety level. Each dog was evaluated 3 times a day at 4 weeks intervals (T1-T2-T3). 15 Each evaluation lasted 2 days and involved a Reactivity Evaluation Form (REF), a 16 blood sampling, heart rate recording and a 10 min behavioral video recording. Results 17 from REF scores showed that while at T1 Anxious dogs had significantly higher scores 18 (Mann-Whitney test: P<0.001) compared to Non-anxious dogs, no difference was found 19 between Anxious dogs fed with CH diet and Non-anxious fed with PD or CH diet at T3. 20 Behavioral observations evidenced some signs of improvement in Anxious dog fed with 21 CH diet. Cortisol level significantly decreased in Anxious dogs fed with CH diet 22 (Friedman test: P<0.05). Individual differences in physiological measures of stress 23 responses may have contributed to the large variability, making interpretation of these 24 measures difficult. These results suggest that CH may be used as a functional ingredient 25 alleviating stress in dogs

Pharmacokinetics and distribution of clioquinol in golden hamsters

Clioquinol (5-chloro-7-iodo-8-quinolinol) is a zinc and copper chelator that can dissolve amyloid deposits and may be beneficial in Alzheimer's disease. Prion diseases are also degenerative CNS disorders characterised by amyloid deposits. The pharmacokinetics and tissue distribution of drugs active against prions may clarify their targets of action. We describe the pharmacokinetics of clioquinol in hamster plasma, spleen and brain after single and repeated oral or intraperitoneal administration (50 mg kg(-1)), as well as after administration with the diet. A single intraperitoneal administration led to peak plasma clioquinol concentrations after 15 min (Tmax), followed by a decay with an apparent half-life of 2.20 +/- 1.1 h. After oral administration, Tmax was reached after 30 min and was followed by a similar process of decay; the AUC(0-last) was 16% that recorded after intraperitoneal administration. The Cmax and AUC values in spleen after a single administration were about 65% (i.p.) and 25% (p.o.) those observed in blood; those in liver were 35% (p.o.) those observed in blood and those in brain were 20% (i.p.) and 10% (p.o.) those observed in plasma. After repeated oral doses, the plasma, brain and spleen concentrations were similar to those observed at the same times after a single dose. One hour after intraperitoneal dosing, clioquinol was also found in the ventricular CSF. Clioquinol was also given with the diet; its morning and afternoon concentrations were similar, and matched those after oral administration. No toxicity was found after chronic administration. Our results indicate that clioquinol, after oral administration with the diet, reaches concentrations in brain and peripheral tissues (particularly spleen) that can be considered effective in preventing prion accumulation, but are at least ten times lower than those likely to cause toxicity